Eevia Health Plc

Eevia Health Plc has announced a delay in publishing its Interim Report for the third quarter, now scheduled for release on November 29, 2024. This postponement is due to the onboarding of a new Board and an unforeseen urgent project that requires significant attention. The new Board was elected on November 4 and is still in the process of being inducted. The next Board meeting on November 20 will focus on this urgent project, necessitating more time for the review of the Interim Report. Eevia Health, founded in 2017, produces bioactive compounds from plant materials, primarily sourced from Finnish and Swedish forests. The company operates a green-chemistry production facility in Finland and is listed on the Spotlight Stock Market in Sweden. For more information, contact Stein Ulve, CEO, via email or phone.

Eevia Health Plc has received a 51,000 euro sales order from a European nutraceutical brand owner based in Sweden. The customer, which markets herbal dietary supplements and cosmetics in over 50,000 retail outlets across 38 countries, including China and the USA, has placed a repeat order for Feno-Myrtillus® 1, a bilberry extract standardized for anthocyanins. Eevia was chosen for its high quality and product authenticity. Founded in 2017, Eevia Health produces bioactive compounds from plant materials, primarily wild-harvested from Finnish and Swedish forests, and sells them as ingredients for dietary supplements globally. The company operates a green-chemistry production facility in Finland and is listed on the Spotlight Stock Market in Sweden.

Eevia Health Plc announced a correction regarding its earlier press release about negotiations with a European food manufacturer for a new plant extract product. Initially expected to significantly boost Eevia's revenue and profits in 2025, the project has faced delays due to cost and other issues, leading to a lack of significant volume commitments for 2025. The parties are now discussing single orders on a case-by-case basis, with a new order anticipated for December. Eevia has proposed a new technology to reduce costs, but no commercial contract for larger volumes has been agreed upon. Eevia does not expect significant order commitments in 2025 but remains open to future participation in the project. Eevia Health, founded in 2017, specializes in bioactive plant extracts, primarily sourced from wild-harvested materials in Finland and Sweden. The company operates an eco-friendly production facility in Finland and is listed on the Spotlight Stock Market in Sweden.

Eevia Health PLC received several sales orders totaling KEUR 56 from European and Asian customers. Orders include KEUR 18 from distributor Breko for various organic extracts, KEUR 21 from a Swedish nutraceutical brand, KEUR 9 from Finnish customers, and KEUR 8 from a regular customer in Taiwan. The products ordered are in stock and beneficial for operational cash flow. Eevia Health, founded in 2017, produces bioactive compounds from wild-harvested plant materials in Finland and Sweden. The company manufactures 100% organically certified plant extracts used in dietary supplements and food brands globally. Eevia operates a green-chemistry production facility in Finland, emphasizing sustainability and transparency. For more information, contact Stein Ulve, CEO, at stein.ulve@eeviahealth.com or investor@eeviahealth.com, or call +358 400 22 5967.

Stein Ulve, CEO of Eevia Health Plc, has purchased 525,700 shares in the company through a recent Rights issue, at a price of EUR 0.05 per share, totaling EUR 26,285. Before this purchase, Ulve held 2,284,714 shares, representing 6.40% of the outstanding shares. Now, he holds 2,810,414 shares, which equals 3.55% of the current outstanding shares due to dilution from the Rights issue. Ulve also received 131,425 Warrants TO1 as part of the subscription, with the subscription period set for August 2025. Eevia Health Plc, founded in March 2017, produces bioactive compounds from wild-harvested plant materials, primarily from Finnish and Swedish forests. The company is listed on the Spotlight Stock Market in Sweden. For more information, visit www.eeviahealth.com.

Eevia Health PLC has received sales orders totaling KEUR 92 for its extracts from customers in Europe, Australia, and the US. Notable orders include KEUR 44 from NutriOriginal in the US for various organic mushroom and bilberry extracts, KEUR 18 from Ingredients Plus in Australia for elderberry extract, and KEUR 30 from a French trading partner for bilberry extract. These orders are repeat purchases, indicating strong customer demand and contributing positively to cash flow as the products are already in stock. Eevia expects continued repeat orders due to the growing interest in mushroom-based dietary supplements. For more information, contact Stein Ulve, CEO of Eevia Health. Eevia Health, founded in 2017, produces bioactive compounds from wild-harvested plant materials in Finland and Sweden. The company focuses on sustainability and operates a green-chemistry production facility. Eevia Health is listed on the Spotlight Stock Market in Sweden under the ticker EEVIA.

Eevia Health PLC has received its first sales order from a new pilot customer for two of its liquid sugar concentrates, derived as side streams from berry extract production. This order is valued at approximately EUR 30,000. Eevia has been focusing on sustainability by valorizing its side streams, including liquid sugars and organic acids, which were previously discarded. The company has developed a new product, Liquid Sugar Concentrate, and successfully tested concentrating the liquid to 65% solids. The pilot customer, a North European berry product operator headquartered in Benelux, will receive eight tons of Bilberry Liquid Sugar concentrate and two tons of Tart Cherry Liquid Sugar concentrate. This development is expected to significantly enhance Eevia's product profitability. Eevia Health, founded in 2017, manufactures bioactive compounds from wild-harvested plant materials and operates a green-chemistry production facility in Finland. The company is listed on the Spotlight Stock Market in Sweden under the ticker EEVIA.

Eevia Health Plc's rights issue has been registered with the Finnish Trade Register, and the shares have been delivered to Euroclear Sweden and Euroclear Finland. The paid subscription shares will be replaced by ordinary shares, which will be booked into custodian accounts by August 22, 2024, and available on August 23, 2024. The last trading day for BTA on Spotlight Stock Market is August 19, 2024. The rights issue raised approximately SEK 17.2 million, increasing the number of shares from 35,713,884 to 64,355,488. Partner Fondkommission and OP Bank acted as financial advisers and issuing agents in Sweden and Finland, respectively. Eevia Health Plc, founded in 2017, produces bioactive compounds from wild-harvested plant materials, primarily from Finnish and Swedish forests. The company operates a green-chemistry production facility in Finland and is listed on the Spotlight Stock Market in Sweden. For more information, visit their website or LinkedIn page.

Eevia Health Plc has received an 80,000 EUR sales order for customized lingonberry extracts from a renowned Finnish beauty brand. The end customer, a well-known manufacturer in the cosmetics industry, markets premium products across Europe, Asia, and North America, and is committed to sustainable development and natural Arctic product lines. The lingonberry extracts are standardized on key polyphenols and produced using a specialized processing protocol for this customer. This order is part of the expected repeat sales. Eevia Health Plc, founded in March 2017, focuses on addressing health problems with bioactive compounds from wild-harvested plant materials in Finland and Sweden. The company manufactures organically certified plant extracts for dietary supplements and food brands globally. Eevia Health emphasizes sustainable practices, operating a green-chemistry production facility in Finland, and listed its shares on the Spotlight Stock Market in Sweden in June 2021. For more information, visit www.eeviahealth.com or follow Eevia Health on LinkedIn @EeviaHealth.

Eevia Health Plc announced the results of its rights issue, which concluded on June 28, 2024, in Sweden and July 2, 2024, in Finland. A total of 28,360,404 shares were allocated, representing 59.6% of the offered shares. Existing shareholders subscribed to 18,629,364 shares with rights, while both existing and new shareholders subscribed to another 9,731,040 shares without rights. The company will issue 7,090,096 warrants of series TO1 and raise approximately SEK 17.0 million before costs, which are estimated at SEK 2.5 million. The funds will enhance working capital and repay a short-term bridge loan of SEK 7.5 million plus interest. The new shares are expected to be registered and delivered to subscribers by late July 2024. The rights issue will result in a 44.3% dilution for non-participating existing shareholders. Partner Fondkommission and OP Bank are the financial advisers and issuer agents for the offer in Sweden and Finland, respectively.